ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying ...

Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives ...

As of Friday, January 09, Aquestive Therapeutics, Inc.’s AQST share price has dipped by 37.28%, which has investors ...

New guidelines help non-medics correctly identify acute allergic reactions requiring epinephrine administration ...

neffy is commercially available in the U.S. for the emergency treatment of allergic reactions, including anaphylaxis, in ...

Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising ...

New recommendations for administering epinephrine during acute allergic reactions (AAR) are expected to significantly improve ...

Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On ...

A number of new health care-related laws have taken effect in Illinois, including one that mandates implicit bias awareness ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

A single-institution US study in the Journal of Allergy and Clinical Immunology: Global has reported a steady rise in ...